An update on immunotherapy options for urothelial cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34. PubMed PMID: 30620402.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068–3077. PubMed PMID: 11001674.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001 May 15;19(10):2638–2646. PubMed PMID: 11352955.
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10;30(2):191–199. PubMed PMID: 22162575; PubMed Central PMCID: PMCPMC3255563.
   PubMed Web of Science ®Google Scholar
• Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016 Jun;102:37–46. PubMed PMID: 27105947.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454–4461. PubMed PMID: 19687335.
   PubMed Web of Science ®Google Scholar
• Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998 Jul;34(8):1208–1212. PubMed PMID: 9849481.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002 Feb 15;20(4):937–940. PubMed PMID: 11844814.
   PubMed Web of Science ®Google Scholar
• Koshkin VS, Grivas P. Emerging role of immunotherapy in advanced urothelial carcinoma. Curr Oncol Rep. 2018 Apr 11;20(6):48. PubMed PMID: 29644490. .
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11;499(7457):214–218. PubMed PMID: 23770567; PubMed Central PMCID: PMCPMC3919509.
   PubMed Web of Science ®Google Scholar
• Liontos M, Anastasiou I, Bamias A, et al. DNA damage, tumor mutational load and their impact on immune responses against cancer. Ann Transl Med. 2016 Jul;4(14):264. PubMed PMID: 27563651; PubMed Central PMCID: PMCPMC4971372.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67–76. PubMed PMID: 27939400; PubMed Central PMCID: PMCPMC5568632.
   PubMed Web of Science ®Google Scholar
• [cited 2016 May 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf
   Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909–1920. PubMed PMID: 26952546; PubMed Central PMCID: PMCPMC5480242.
   PubMed Web of Science ®Google Scholar
• Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017 Dec 18. PubMed PMID: 29268948. DOI:10.1016/S0140-6736(17)33297-X.
   Google Scholar
• Castellano D, Ravaud A, Maillet D, et al. 899PA phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). Ann Oncol. 2018;29(suppl_8). DOI:10.1093/annonc/mdy283.108
   Google Scholar
• O’Donnell PH, Grivas P, Balar AV, et al. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol. 2017;35(15_suppl):4502–4502.
   Google Scholar
• Grivas P, Bajorin D, Ellison MC, et al. 857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status. Ann Oncol. 2017;28(suppl_5). DOI:10.1093/annonc/mdx371.011
   Google Scholar
• Vuky J, Balar AV, Castellano DE, et al. Updated efficacy and safety of KEYNOTE-052: a single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol. 2018;36(15_suppl):4524–4524.
   Web of Science ®Google Scholar
• [cited 2017 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s017s018lbl.pdf
   Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015–1026. PubMed PMID: 28212060; PubMed Central PMCID: PMCPMC5635424.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase ii study. J Clin Oncol. 2018 Oct 20:JCO1801148. PubMed PMID: 30343614. DOI:10.1200/JCO.18.01148.
   PubMedGoogle Scholar
• Balar AV, Kulkarni GS, Uchio EM, et al. Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). J Clin Oncol. 2019;37(7_suppl):350–350.
   PubMed Web of Science ®Google Scholar
• Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016 Nov;17(11):1590–1598. PubMed PMID: 27733243; PubMed Central PMCID: PMCPMC5648054.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Sharma P, de Braud FGM, et al. LBA32Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. Ann Oncol. 2018;29(suppl_8):mdy424.038-mdy424.038.
   Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312–322. PubMed PMID: 28131785.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Feb 2]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf
   Google Scholar
• Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018 Jan;19(1):51–64. PubMed PMID: 29217288.
   PubMed Web of Science ®Google Scholar
• [cited 2017 May 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761078s000lbl.pdf
   Google Scholar
• Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119–3125. PubMed PMID: 27269937; PubMed Central PMCID: PMCPMC5569690.
   PubMed Web of Science ®Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017 Sep 14;3(9):e172411. PubMed PMID: 28817753; PubMed Central PMCID: PMCPMC5824288.
   PubMed Web of Science ®Google Scholar
• [cited 2017 May 02]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf
   Google Scholar
• Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130). ClinicalTrials.gov identifier: NCT02807636. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract. ClinicalTrials.gov identifier: NCT02928406. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase iii, open-label, multicenter, randomized study of atezolizumab (Anti-PD-L1 Antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection. ClinicalTrials.gov identifier: NCT02450331. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Atezolizumab with or without eribulin mesylate in treating patients with recurrent locally advanced or metastatic urothelial cancer. ClinicalTrials.gov identifier: NCT03237780. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer (Study SWOG/NRG 1806). ClinicalTrials.gov identifier: NCT03775265. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Study of cabozantinib in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors. ClinicalTrials.gov identifier: NCT03170960. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Study of pembrolizumab (MK-3475) in participants with high risk non-muscle invasive bladder cancer (MK-3475-057/KEYNOTE-057). ClinicalTrials.gov identifier: NCT02625961. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). ClinicalTrials.gov identifier: NCT03534804. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Single-arm phase ii combination study of low-dose paclitaxel with pembrolizumab in platinum-refractory urothelial carcinoma. ClinicalTrials.gov identifier: NCT02581982. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase iii randomized, controlled clinical trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma. ClinicalTrials.gov identifier: NCT02853305. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in recurrent or progressive metastatic urothelial carcinoma (KEYNOTE-698/ECHO-303). ClinicalTrials.gov identifier: NCT03374488. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Phase III randomized adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) versus observation. ClinicalTrials.gov identifier: NCT03244384. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A randomized, double-blinded, phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer: hoosier cancer research network GU14-182. ClinicalTrials.gov identifier: NCT02500121. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 3, randomized, double-blind study to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus pembrolizumab and placebo as first line treatment for locally advanced or metastatic urothelial carcinoma in cisplatin-ineligible participants whose tumors express PD-L1, and in participants ineligible for any platinum-containing chemotherapy regardless of PD-L1 expression (LEAP-011). ClinicalTrials.gov identifier: NCT03898180. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Tailored immunotherapy approach with nivolumab in subjects with metastatic or advanced transitional cell carcinoma (TITAN-TCC). ClinicalTrials.gov identifier: NCT03219775. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Nivolumab and radiation therapy in treating patients with localized/locally advanced urothelial bladder cancer ineligible for chemotherapy. ClinicalTrials.gov identifier: NCT03421652. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• An Investigational immuno-therapy study of nivolumab, compared to placebo, in patients with bladder or upper urinary tract cancer, following surgery to remove the cancer (CheckMate 274). ClinicalTrials.gov identifier: NCT02632409. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD-L1 expression. ClinicalTrials.gov identifier: NCT03785925. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study of avelumab in patients with locally advanced or metastaticurothelial cancer (JAVELIN Bladder 100). ClinicalTrials.gov identifier: NCT02603432. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• Avelumab plus carboplatin-gemcitabine in urothelial carcinoma. ClinicalTrials.gov identifier: NCT03390595. [cited 2018 Sept 2]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase III, randomized, open-label, controlled, multi-center, global study of first-line MEDI4736 (Durvalumab) monotherapy and MEDI4736 (Durvalumab) in combination with tremelimumab versus standard of care chemotherapy in patients with unresectable stage IV urothelial cancer. ClinicalTrials.gov identifier: NCT02516241. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase III, randomized, open-label, controlled, multi-center, global study of first-line durvalumab in combination with standard of care chemotherapy and durvalumab in combination with tremelimumab and standard of care chemotherapy versus standard of care chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer. ClinicalTrials.gov identifier: NCT03682068. [cited 2019 Apr 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288–2301. PubMed PMID: 29863955.
   PubMed Web of Science ®Google Scholar
• Alexander M, Galeas J, Cheng H. Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell? J Thorac Dis. 2018 Nov;10(Suppl 33):S3994–S3998. PubMed PMID: 30631537; PubMed Central PMCID: PMCPMC6297473.
   PubMedGoogle Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520. PubMed PMID: 26028255; PubMed Central PMCID: PMCPMC4481136.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan D, Koshkin VS, Ornstein MC, et al. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018;14:1019–1040. PubMed PMID: 29892196; PubMed Central PMCID: PMCPMC5993034.
   PubMed Web of Science ®Google Scholar